Symmetry Partners LLC Takes $270,000 Position in STERIS plc (NYSE:STE)

Symmetry Partners LLC acquired a new stake in shares of STERIS plc (NYSE:STEFree Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,202 shares of the medical equipment provider’s stock, valued at approximately $270,000.

A number of other hedge funds have also recently made changes to their positions in the business. VisionPoint Advisory Group LLC purchased a new position in STERIS in the fourth quarter valued at about $34,000. Pingora Partners LLC purchased a new stake in shares of STERIS in the 4th quarter valued at $37,000. Glassman Wealth Services purchased a new stake in shares of STERIS in the 4th quarter valued at $38,000. Spire Wealth Management boosted its stake in shares of STERIS by 88.0% in the 4th quarter. Spire Wealth Management now owns 203 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 95 shares in the last quarter. Finally, AdvisorNet Financial Inc boosted its position in STERIS by 144.9% during the 4th quarter. AdvisorNet Financial Inc now owns 311 shares of the medical equipment provider’s stock valued at $68,000 after buying an additional 184 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other STERIS news, SVP Cary L. Majors sold 2,024 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $232.13, for a total transaction of $469,831.12. Following the transaction, the senior vice president now owns 11,369 shares in the company, valued at $2,639,085.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, SVP Cary L. Majors sold 2,024 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $232.13, for a total transaction of $469,831.12. Following the completion of the sale, the senior vice president now directly owns 11,369 shares of the company’s stock, valued at $2,639,085.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jacqueline B. Kosecoff sold 4,584 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $231.53, for a total transaction of $1,061,333.52. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 7,762 shares of company stock worth $1,798,477. Insiders own 1.14% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on STE shares. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research report on Thursday, May 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Friday, May 10th. Piper Sandler reaffirmed a “neutral” rating and issued a $225.00 target price (up from $220.00) on shares of STERIS in a research report on Friday, May 10th. Finally, StockNews.com upgraded shares of STERIS from a “hold” rating to a “buy” rating in a research note on Saturday. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, STERIS currently has an average rating of “Moderate Buy” and a consensus price target of $241.60.

Read Our Latest Report on STERIS

STERIS Stock Up 0.2 %

NYSE:STE traded up $0.38 on Tuesday, reaching $216.50. 457,734 shares of the stock traded hands, compared to its average volume of 491,705. The company has a market capitalization of $21.40 billion, a price-to-earnings ratio of 56.56 and a beta of 0.85. The company has a current ratio of 3.08, a quick ratio of 2.36 and a debt-to-equity ratio of 0.49. STERIS plc has a 12 month low of $195.47 and a 12 month high of $254.00. The company’s fifty day simple moving average is $217.68 and its 200 day simple moving average is $220.18.

STERIS (NYSE:STEGet Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The medical equipment provider reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.41 by $0.17. STERIS had a net margin of 6.95% and a return on equity of 13.73%. The business had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.41 billion. During the same quarter in the previous year, the firm earned $2.30 earnings per share. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. Equities analysts predict that STERIS plc will post 9.24 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 26th. Investors of record on Wednesday, June 12th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 0.96%. The ex-dividend date is Wednesday, June 12th. STERIS’s dividend payout ratio is presently 54.45%.

STERIS Company Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Featured Articles

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STEFree Report).

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.